SAW PALMETTO NATURES PROSTATE HEALER: THE PROOF IS IN THE FLOW
One of the earliest studies evaluating the role of SP in the therapy of BPH was done in 1984 by Dr. Champault and colleagues at the Hospital Jean Verdier in Bondy, France. These researchers used a trademarked version of SP extract named Permixon, which is owned by a French company called Pierre Fabre Medicaments. (Other trademarks include Capistan, Strogen, Libeprosta and Sereprostat.) Permixon \s main components are free (90%) and esterified (7%) fatty acids, sterols, flavonoids and other substances.
Fifty-five patients with BPH who had symptoms of frequent urination, nocturia, and poor urinary flow were given 160 mg of Permixon twice a day for 30 days. The results were compared to another group who received placebo pills. At the end of this period, both objective measurements of urinary flow and subjective reporting from patients had improved on average by 50 percent compared to placebo. The medicine was well tolerated with only minor side effects reported, one being headaches. Standard blood chemistry measurements showed no changes.
The researchers conclude, "As predicted from pharmacological and biochemical studies, Permixon appears to be a useful therapeutic tool in the treatment of benign prostatic hyperplasia."
It should be noted that many of the studies evaluating the effects of SP were conducted or funded by the pharmaceutical company that sells Permixon, the trademarked version of SP extract.
Champault and colleagues published a follow up study that involved administering Permixon to 47 patients with prostatic adenoma. An adenoma is a benign growth or cancer that has a very low risk of spreading or expanding. The study period this time went for 14 months, and in some cases up to two and a half years. They found the medicine to be efficacious and perfectly tolerated.
Two years later, a British group headed by Dr. Reece Smith, from the Department of Urology and Radiology at Southampton General Hospital, repeated a similar study. Thirty-three patients were given Permixon at 160 mg twice daily and compared to a group of 37 individuals who did not receive any therapy. Interestingly, both the medication treated group and the placebo group had a significant improvement in flow rate and symptoms. No side effects were noted on Permixon except for two patients who had nausea, and one who reported an increase in sexual drive. The researchers did not seem to be completely convinced of SP's benefits. They say, "In conclusion, whilst the regime of Permixon used in this trial was safe, well tolerated and associated with considerable, symptomatic improvement, we have no evidence that this improvement was due to anything more than the psychosocial value of being involved in the trial and meeting a number of sufferers from a similar condition."
With these conflicting reports on the effectiveness of SP, an extensive study was sorely needed. Fortunately, such a study was published in 1996. Not only did it evaluate the effectiveness of SP in the therapy of BPH, but it also compared this herb to Proscar, the medical gold standard in the therapy of BPH.
*22\299\2*
Men's Health Erectile Dysfunction